彭晖（兼职）

发布者：陈洁洋发布时间：2017-03-26浏览次数：4239

                           彭晖，男，1972年1月出生，药理专业，理学博士，研究员，硕士生导师，现为军事医学科学院卫生学环境医学研究所环境药学研究室主任。1992年本科毕业于中国药科大学药物化学专业，1998年硕士毕业于中国协和医科大学药物化学专业，2003年博士毕业于中国协和医科大学分子药理专业；1992年至2004年在实验血液学国家重点实验室从事科研工作，2004至2007年在美国印第安纳大学癌症研究中心做访问学者；2007年由军事医学科学院特招入伍，人才引进。长期从事计算机辅助药物设计、肿瘤耐药分子机制以及逆转研究。承担国家自然基金、863子课题和天津市应用基础研究重点项目以及“十一五”、“十二五”军队新药创制科技重大保密专项等多项课题。已经获得13项专利授权（含国防专利2项），正在申请中6项（含国防专利2项）；在国内外核心期刊发表100余篇署名学术论文，其中SCI文章38篇（总影响因子140，总引用740次以上）；曾获得天津市科技进步一、二、三等奖各1项。目前已培养博士毕业生4名，硕士毕业生6名，其中1名硕士毕业生获得河南省优秀硕士学位论文。

社会兼职情况：军事医学科学院卫生学环境医学研究所科学技术委员会委员，中国医药生物技术协会单克隆抗体专业委员会委员，中国药理学会生化及分子药理学专业委员会委员；国家自然基金、北京市、天津市和河北省自然基金函审评委，国家科技专家库成员，863计划评审专家库成员；《解放军预防医学杂志》编委、中国药理与毒理学杂志、中国药理学通报、国际药学研究杂志、生命的化学和中国应用生理学等多个杂志评审专家，Oncotarget、International Journal of Cancer、PLoS ONE、Current Analytical Chemistry、Mini-reviews in Medicinal Chemistry、Chem & Biodivers等英文杂志审稿专家，福建医科大学药学院客座教授。


研究方向：

  1. 抗肿瘤药物的新药设计与活性评价；

  2. 肿瘤耐药分子网络机制及克服新策略；

  3. 环境与肿瘤药学；


近五年发表SCI论文（按时间排序）

  1. Ren Z, Gu X, Lu B, Chen Y, Chen G, Feng J, Lin J, Zhang Y*, Peng H*. Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug- resistant cancer cells.  J Cell Mol Med. 2016 Jun; 20(6): 1095-105.  IF: 4.938

  2. Huang W, Dong Z, Chen Y, Wang F, Wang CJ, Peng H, He Y, Hangoc G, Pollok K, Sandusky G, Fu XY, Broxmeyer HE, Zhang ZY, Liu JY, Zhang JT. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo.  Oncogene 2016 Feb 11; 35(6): 783- 92.  IF: 7.932

  3. Dong 

  4. N, Luo L, Wu J, Jia P, Li Q, Wang Y, Gao Z, Peng H, Lv M, Huang C, Feng J, Li H, Shan J, Han G, Shen B. Monoclonal antibody, mAb 4C13, an effective detoxicant antibody against ricin poisoning.  Vaccine. 2015 Jul 31; 33(32): 3836- 42.  IF: 3.413

  5. Gu X, Tang X, Zhao Q, Peng H*, Peng S, Zhang Y*. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e] azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.  Bioorg Med Chem Lett. 2014; 24(15): 3419-21  IF: 2.420

  6. Gu X, Ren Z, Peng H*, Peng S, Zhang Y. Bifendate-chalcone hybrids: A new class of potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.  Biochem Biophys Res Commun. 2014 Dec 12; 455(3-4): 318- 322.  IF: 2.297

  7. Huang W#, Dong Z#, Wang F#, Peng H, Liu JY, Zhang JT. A Small Molecule Compound Targeting STAT3 DNA-Binding Domain Inhibits Cancer Cell Proliferation, Migration, and Invasion.  ACS Chem Biol. 2014 May 16; 9(5): 1188-96  IF: 5.331

  8. Xi Y, Wu X, Gao L, Shao Y, Peng H, Chen H, Chen H, Hu X, Yue J. Improving the Anti-Toxin Abilities of the CMG2-Fc Fusion Protein with the Aid of Computational Design.  PLoS One. 2014 Aug 7;9(8): e104674  IF: 3.534

  9. W

  10. ang W, Zhang Y, Lv M, Feng J, Peng H, Geng J, Lin Z, Zhou T, Li X, Shen B, Ma Y, Qiao C. Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3.  J Ovarian Res. 2014; Nov 26; 7(1): 103.  IF: 2.428

  11. Jia Y; Zhang Y, Qiao C, Liu G, Zhao Q, Zhou T, Chen G, Li Y, Feng J, Li Y; Zhang Q*, Peng H*; IGF-1R and ErbB3/HER3 Contribute to Enhanced Proliferation and Carcinogenesis in Trastuzumab-resistant Ovarian Cancer model.  Biochem Bioph Res Comm2013; 436(4): 740-745.IF: 2.281

  12. Zhang SL, Wei YX, Li Q, Sun HP, Peng H*, You QD*; Pharmacophore-based drug design and biological evaluation of novel ABCB1 inhibitors.  Chem Biol Drug Des. 2013; 81(3): 349-358. IF: 2.507

  13. Li Z, Peng H, Qin L, Qi J, Zuo X, Liu JY, Zhang JT; Determinants of 14-3-3δ protein dimerization and function in drug and radiation resistance.  J Biol Chem. 2013; 288(44): 31447-31457. IF: 4.6

  14. Dong Z, Qi J, Peng H, Liu J, Zhang JT; Spectrin domain of eukaryotic initiation factor 3a is the docking site for formation of the a:b:i:g subcomplex.  J Biol Chem. 2013; 288(39): 27951-27959  IF: 4.6

  15. Wang Q, Feng J, Wang J, Zhang X, Zhang D, Zhu T, Wang W, Wang X, Jin J, Cao J, Li X, Peng H, Li Y, Shen B, Zhang J; Disruption of TAB1/p38α Interaction Using a Cell-permeable Peptide Limits Myocardial Ischemia/Reperfusion Injury.  Mol Ther. 2013; 21(9): 1668-77  IF: 6.425

  16. Wei Y, Ma Y, Zhao Q, Ren Z, Li Y, Hou T*, Peng H*; New use for an old drug: inhibiting ABCG2 with sorafenib.  Mol Cancer Ther. 2012; 11(8): 1693-1702  IF: 5.599

  17. Tang X, Gu X, Ren Z, Ma Y, Lai Y, Peng H*, Peng S, Zhang Y*; Synthesis and evaluation of substituted dibenzo[c,e]azepine-5-ones as P-glycoprotein-mediated multidrug resistance reversal agents.  Bioorg Med Chem Lett. 2012; 22(8): 2675-80  IF: 2.338

  18. Gu X, R

  19. en Z, Tang X, Peng H*, Ma Y, Lai Y, Peng S, Zhang Y*; Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors.  Bioorg Med Chem. 2012; 20(8): 2540-8 IF: 2.903

  20. Gu X, Ren Z, Tang X, Peng H*, Zhao Q, Lai Y, Peng S, Zhang Y*; Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro- dibenzo [c,e]azepine scaffold as potent P-glycoprotein inhibitors.  Eur. J. Med. Chem. 2012; 51: 137-144.  IF: 3.499

  21. Tang X, Gu X, Ai H, Wang G, Peng H, Lai Y, Zhang Y; Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells.  Bioorg Med Chem Lett. 2012; 22(2): 801-5 IF: 2.338

  22. Chen L, Li Y, Zhao Q, Peng H*, Hou T*; ADME Evaluation in Drug Discovery. 10. Predictions of P-Glycoprotein Inhibitors using Recursive Partitioning and Naïve Bayesian Classification Techniques.  Mol Pharmaceutics2011; 8(3): 889-900.  IF: 5.4

  23. Wei H¶, Lin Z¶, Feng J¶, Peng H, Guo R, Han G, Geng S, Lang X, Sun Y, Shen B, Li Y;  Identification of conformational core epitope Lys68 in C5a based on the 3-D modeling complex C5a and its functional antibody F20.  Mol Immunol. 2011; 48(12-13): 1377-83 IF: 2.897

  24. Li Y, Feng J, Geng S, Geng S, Wei H, Chen G, Li X, Wang L, Wang R, Peng H, Han G, Shen B, Li Y.  The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple f

  25. unctions in innate immunity and adaptive immunity.Mol Immunol. 2011; 48(4): 670-7.  IF: 2.897

  26. Zhang Y, Yang M, Ji Q, Fan D, Peng H, Yang C, Xiong D, Zhou Y; Anoikis induction and metastasis suppr

  27. ession by a new integrin αvβ3 inhibitor in human melanoma cell line M21.  Invest New Drugs 2011; 29: 666-73  IF: 3.357

  28. Wu J, Wang Y, Jia P, Wang C, Zhao Y, Peng H, Wei W, Li H； Immunochromatography detection of ricin in environmental and biological samples.  Nano Biomed. Eng. 2011; 3(3), 167-171

  29. Peng H, Qi J, Dong Z, Zhang JT; Dynamic vs Static ABCG2 Inhibitors to Sensitize Drug Resistant Cancer Cells.  PLoS ONE 2010; 5(12): e15276IF: 4.411

  30. Peng H, Dong Z, Qi J, Yang Y, Liu Y, Li Z, Xu J, Zhang JT;  A Novel Two Mode-Acting Inhibitor of ABCG2-mediated Multidrug Transport and Resistance in Cancer Chemotherapy.  PLoS ONE 2009; 4(5): e5676  IF: 4.351

  31. Liu Y, Yang Y, Qi J, Peng H, Zhang JT; Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2.  J Pharmacol Exp Ther. 2008; 326(1): 33-40  IF: 4.309

  32. Xu J, Peng H, Zhang JT. Human Multidrug Transporter ABCG2, a Target for Sensitizing Drug Resistance in Cancer Chemotherapy.  Curr Med Chem. 2007; 14: 689-701  IF: 4.944

  33. Xu J, Peng H, Chen Q, Liu Y, Dong Z, Zhang JT; Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity.  Cancer Res. 2007; 67(9): 4373-81  IF: 7.672

  34. Yang Y, Liu Y, Dong Z, Xu J, Peng H, Liu Z, Zhang JT;  Regulation of function by dimerization throug

  35. h the amino terminal membrane-spanning domain of human ABCC1/MRP1.  J Biol Chem. 2007; 282(12): 8821-30  IF: 4.773


获奖情况：

1．“血液肿瘤耐药机制及克服耐药研究” （编号：2004JB-1-007）

2005年天津市科技进步一等奖

2．“亲溶酶体剂净化白血病骨髓药物构效关系研究” （编号：2001JB-3-121）

2002年天津市科技进步三等奖

3．“抗CD3和抗CD20双功能抗体的研制” （编号：2001JB-2-029）

2002年天津市科技进步二等奖


联系方式：

联系地址：北京市海淀区太平路27号军医科四所十室，邮编：100850

联系电话：010-66931554（O），13910146703

Email：p_h2002@hotmail.com